Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.